SARS-CoV-2 Lin. JN.1; Omicron Var. (USA/NY/PV96109/2023) – CFHI

SARS-Related Coronavirus 2 Lineage JN.1; Omicron Variant (Isolate: USA/New York/PV96109/2023) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/New York/PV96109/2023 was isolated from a human nasopharyngeal swab in 2023, in New York, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/New York/PV96109/2023 is assigned lineage JN.1 (Pango v.4.3.1 consensus call), Omicron (BA.2-like) (Scorpio) and GISAID clade GRA using the Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. The complete genome of SARS-CoV-2 isolate hCoV-19/USA/New York/PV96109/2023 has been sequenced (GISAID:EPI_ISL_18563626). It was labeled as a variant of interest (VOI) GRA (BA.2.86+BA.2.86.*), and first detected in Denmark/lsrael/USA by the World Health Organization (WHO).

Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability and
performance characteristics should be determined by your laboratory for each intended usage. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

-20° C.
Product Insert.pdf

Material Safety Data Sheet.pdf